PI3K pathway as a major determinant of resistance to HER2-targeted therapy in advanced gastric cancer

被引：0
|
作者：
Kim, Hyo Song
Zhang, Xianglan
Park, Kyu Hyun
Park, Ji Soo
Kim, Ki Hyang
Chung, Hyun Cheol
Rha, Sun Young
机构：
[1] Yonsei Univ Coll Med, Dept Internal Med, Seoul, South Korea
[2] Yonsei Univ Coll Dent, Oral Canc Res Inst, Seoul, South Korea
[3] Yonsei Univ Coll Med, Canc Metastasis Res Ctr, Seoul, South Korea
[4] Yonsei Univ Coll Med, Div Med Oncol, Dept Internal Med, Yonsei Canc Ctr, Seoul, South Korea
[5] Inje Univ Coll Med, Busan Paik Hosp, Div Hematol Oncol, Dept Internal Med, Pusan, South Korea
[6] Yonsei Univ Heath Syst, Yonsei Canc Ctr, Seoul, South Korea
[7] Yonsei Univ Coll Med, Yonsei Canc Ctr, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4089
引用
收藏
页数：1
相关论文
共 50 条
  • [21] HER2-targeted therapy: an emerging strategy in advanced colorectal cancer
    La Salvia, Anna
    Lopez-Gomez, Victoria
    Garcia-Carbonero, Rocio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (01) : 29 - 38
  • [22] Plasma ctDNA mutation anaysis for identification of initial and acquired resistance to HER2-targeted therapy in advanced gastric cancer patients
    Gaye, E.
    Bellosillo Paricio, B.
    Visa, L.
    Iglesias Coma, M.
    Sanchez Martin, F. J.
    Sampera Borras, A.
    Montagut Viladot, C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [23] PI3K inhibitors overcome resistance to HER2-targeted agents caused by PIK3CA mutations in HER2-amplified breast cancer cell lines
    Kataoka, Yu
    Minami, Hironobu
    Shimada, Hiroyuki
    Saijo, Nagahiro
    Hirai, Midori
    Mukohara, Toru
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [24] The tumor immune microenvironment remodeling and response to HER2-targeted therapy in HER2-positive advanced gastric cancer
    Jiang, Lei
    Zhao, Xingwang
    Li, Yilin
    Hu, Yajie
    Sun, Yu
    Liu, Shengde
    Zhang, Zizhen
    Li, Yanyan
    Feng, Xujiao
    Yuan, Jiajia
    Li, Jian
    Zhang, Xiaotian
    Chen, Yang
    Shen, Lin
    IUBMB LIFE, 2024, 76 (07) : 420 - 436
  • [25] Molecular mechanisms of resistance to HER2-targeted therapy
    FJ Esteva
    Breast Cancer Research, 11
  • [26] Targeting the PI3K pathway for cancer therapy
    Sadeghi, Navid
    Gerber, David E.
    FUTURE MEDICINAL CHEMISTRY, 2012, 4 (09) : 1153 - 1169
  • [27] PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers
    Q Wang
    P Liu
    J M Spangle
    T Von
    T M Roberts
    N U Lin
    I E Krop
    E P Winer
    J J Zhao
    Oncogene, 2016, 35 : 3607 - 3612
  • [28] PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers
    Wang, Q.
    Liu, P.
    Spangle, J. M.
    Von, T.
    Roberts, T. M.
    Lin, N. U.
    Krop, I. E.
    Winer, E. P.
    Zhao, J. J.
    ONCOGENE, 2016, 35 (27) : 3607 - 3612
  • [29] Molecular mechanisms of resistance to HER2-targeted therapy
    Esteva, F. J.
    BREAST CANCER RESEARCH, 2009, 11 : S10 - S10
  • [30] Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab
    Diaz-Serrano, Asuncion
    Angulo, Barbara
    Dominguez, Carolina
    Pazo-Cid, Roberto
    Salud, Antonieta
    Jimenez-Fonseca, Paula
    Leon, Ana
    Carmen Galan, Maria
    Alsina, Maria
    Rivera, Fernando
    Plaza, J. Carlos
    Paz-Ares, Luis
    Lopez-Rios, Fernando
    Gomez-Martin, Carlos
    ONCOLOGIST, 2018, 23 (09): : 1092 - 1102
12345